In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal ...

In this randomized controlled trial, patients with metabolic syndrome who underwent time-restricted eating in addition to ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2.

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of... No ads & unlimited access to all current ...

Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...

1. Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...

1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...